MADELEINE VERDOLINO: Open Payments
NPI 1538800123 · ATTLEBORO, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,558 in 121 payments from 13 companies in 2025. Trend: 2023 $1,355 · 2024 $1,941 · 2025 $2,558
Food & beverage: $2,558
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 34 | $679 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $340 |
| ABBVIE INC. | 17 | $296 |
| Teva Pharmaceuticals USA, Inc. | 6 | $237 |
| Alkermes, Inc. | 12 | $218 |
| Janssen Pharmaceuticals, Inc | 11 | $206 |
| Braeburn Inc. | 3 | $129 |
| Indivior Inc. | 5 | $127 |
| Neurocrine BioSciences, Inc. | 5 | $125 |
| E.R. Squibb & Sons, L.L.C. | 4 | $96 |
Products named: REXULTI, CAPLYTA, VRAYLAR, ARISTADA, INVEGA SUSTENNA, AUSTEDO XR, BRIXADI, SUBLOCADE.
Industry payments across MA — which companies pay providers there.
